INTRODUCTION
Spirometry is an extremely useful investigation in pulmonary medicine. In chronic
diseases such as asthma, it is grossly under-utilized, not only in India but in other
countries as well. Besides lack of facilities for good spirometry in most cities and
towns, and inadequate attention to quality control even where it is available, there
is often a poor comprehension and uncertainty on why, when and how often it should
be advised as well as on its clinical applications. This commentary examines several
issues related to the use of spirometry in asthma.
Diagnosis of asthma
Airways obstruction and its reversibility
While a clinical evaluation of the cluster of symptoms and the pattern of their occurrence
is usually sufficient to provide a diagnosis of asthma and start treatment, demonstration
of airways obstruction and its reversibility (a greater than 12% and 200 ml increase
in FEV1) following inhalation of a bronchodilator is recommended to confirm the clinical
diagnosis.[1] A normal spirometry in the presence of symptoms raises the possibility
of an alternative diagnosis. In patients with an apparently difficult asthma, the
finding of a normal spirometry also suggests a wrong diagnosis.
In a quality-assured spirometry, a reduced ratio of FEV1 to FVC indicates airflow
limitation.[2] It is not often realized that the GOLD definition of airways obstruction
(a post-bronchodilator ratio of less than 70%) is strictly applicable only to Chronic
Obstructive Pulmonary Disease (COPD) and not to other airway diseases. The diagnosis
of airways obstruction, in general, is made using the pre-bronchodilator ratio of
FEV1 to FVC showing a value less than the lower limit of normal (LLN).[2] The LLN
is defined as the predicted value minus (1.645 x standard error of estimate). The
predicted value and the standard error of estimate are derived from the reference
equations for the population. In children, the ratio may normally be as high as 90%.
Yet, spirometry has limitations. In patients who are well-controlled on treatment
or in complete remission, it may be normal. Patients with near-normal spirometry or
severe asthma may not show reversibility of airways obstruction due to airway remodelling.
A proportion of patients with COPD may have significant reversibility.[3] Thus, acute
response to bronchodilator has limited value in differentiating asthma from COPD and
spirometry should not be used in isolation to establish a diagnosis of asthma, rather,
used only to support and confirm a clinical suspicion.[4]
Variability of airways obstruction
Variability of airway caliber, either spontaneously or with treatment, is the characteristic
and defining feature of asthma and may be demonstrated either by a large improvement
or deterioration in spirometry. This requires serial spirometry over a few days or
weeks and is also confirmatory of a diagnosis of asthma.[1] An increase or decrease
in FEV1 of >12% and >200 mL from baseline documents variability and may be useful
in patients in whom an acute bronchodilator response is not observed.
Airway hyperresponsiveness
In patients with a normal spirometry, variability may also be demonstrated by bronchial
provocation testing to assess airway hyper-responsiveness. Most often a challenge
with inhaled methacholine is used but an exercise challenge also provides the same
information. The response is measured by spirometry. If the estimated dose of methacholine
producing a 20% decrease in FEV1 (called Provocation concentration, PC20) is less
than 8 mg/ml, the bronchial challenge test is considered positive.[5] However, because
of only a moderate specificity, a positive test is not necessarily diagnostic of asthma.
An exercise challenge producing a 10% decrease in FEV1 a few minutes after stopping
exercise indicates exercise-induced bronchospasm.[6] However, the test has a limited
sensitivity and therefore is not reliable as a diagnostic test for asthma but only
confirms the role of exercise as a triggering factor.
Assessment of control of asthma
The GINA 2014 has defined two domains to assess and monitor the response to treatment:
Assessment of control and determination of risk of future adverse outcomes.[1]
Assessment of control
An assessment of control is required on every follow-up visit to take a decision on
any change in treatment. The proposed method in the current GINA guidelines is based
on assessment of daytime and night-time symptoms, use of rescue bronchodilator and
activity limitation. Spirometry is not required to step-up the treatment.[1] However,
use of validated control instruments, such as the Asthma Control Questionnaire (ACQ)
has an item on the FEV1 value.[7] On the other hand, the other frequently used instrument,
the Asthma Control Test (ACT) does not require spirometry.[8]
Assessment of risk of adverse future outcomes
Lung function is an informative indicator of the future risk of adverse outcomes.
A low FEV1, <60% predicted is a potentially modifiable independent risk factor for
exacerbations besides being a risk factor for developing fixed airflow limitation.[9
10
11] Serial testing may identify patients with a faster decline in lung function.
Attainment of goals of management
One of the goals of management of asthma is to attain normal or near-normal lung function.[1]
While this is a realistic goal in most patients, a significant proportion of patients,
especially those with a moderate or severe disease may never attain a normal lung
function. These patients are generally more difficult to manage having developed an
“irreversible” component due to airway remodelling. During the course of management,
spirometry carried out on optimum treatment and when the patient is well-controlled
would show whether the lung function has been normalized.
Other issues in spirometry in asthma
Frequency of testing
Considering the multiple applications of spirometry in asthma discussed above, it
is not possible to make a recommendation of the frequency of testing. How often to
carry out spirometry during the course of a follow-up is an individualized decision
and also depends on what information is sought from the test. The GINA 2014 report
makes a very broad suggestion that lung function should be measured at diagnosis and
start of treatment, 3-6 months after starting controller treatment, and then periodically.[1]
Should bronchodilator responsiveness be assessed on every visit?
Demonstration of reversibility of airways is part of the diagnostic work-up and therefore
should normally be required only initially. Sometimes, acute reversibility may not
be evident at the first evaluation but may be observed on a subsequent visit. Once
the diagnosis is confirmed, further testing may be restricted to pre-bronchodilator
spirometry as management decisions are not based on bronchodilator responsiveness
but on assessment of control.
Is drug withdrawal necessary at each test?
At the time of establishing the diagnosis, spirometry should be carried out before
and after administration of 400 µg salbutamol using a metered dose inhaler. This requires
an overnight withdrawal of short-acting bronchodilators and 24 hours for longer acting.[12]
Once the diagnosis of asthma has been confirmed, drug withdrawal is generally not
necessary as patients now need to be assessed for their functional status while on
medication. However, comparisons of serial tests should only consider pre-bronchodilator
values.
The concept of personal best test
When spirometry is carried out for the first time, the data is compared with predicted
values. However, predicted values are not necessarily the goal or the target of treatment.
There is a wide range of normal values around the predicted values which only represent
the 50th percentile. A patient's “normal” value may be anywhere between the LLN and
predicted values or even above it. There is no upper limit of normal in spirometry.
Thus, a patient's “personal best” value needs to be established and is usually the
one obtained during a period of complete control with optimum treatment. This then
serves as the goal for subsequent assessments. It needs to be emphasized that a patient's
personal best may be below the LLN if airway remodelling has occurred leading to persistent
obstruction.
How should the change in forced vital capacity be interpreted?
A 12% and 200-ml increase in FEV1 or FVC indicates bronchodilator responsiveness.[2
12] However, both GINA[1] and British 2014 Asthma guidelines[13] are silent on the
use of FVC as a parameter of evaluation. We have previously shown that majority of
patients of asthma respond acutely to a bronchodilator with either an increase in
both FEV1 and FVC or only FEV1 when FVC is in the normal range.[3] However, some asthmatics,
especially those with severe airways obstruction and air trapping may respond with
an isolated FVC response that may be overlooked if only FEV1 is considered.[3]
Defining severity of asthma
The previous classification of severity by the GINA guidelines into mild intermittent
and persistent (mild/moderate/severe) was based on symptoms, activity limitation and
the FEV1 value.[14] However, the 2014 GINA guidelines have excluded spirometry for
classifying the severity of asthma. Severity is now assessed retrospectively from
the level of treatment required to control symptoms and exacerbations and categorized
into mild, moderate and severe.[1]
Can spirometry results be used to change treatment?
The GINA-recommended stepping-up of treatment is based on assessment of control and
not on spirometry.[1] Whereas stepping-up treatment in a symptomatic patient is logical,
an upward revision of treatment in poor perceivers requires spirometry. Spirometry
is useful in identifying patients who perceive symptoms poorly and thus in whom a
symptom-based assessment of control is likely to overestimate the level of control
and result in under-treatment.
The GINA 2014 guidelines recommend stepping down of treatment once good control has
been maintained for 3 months. However, stepping down treatment without normalizing
the lung function or achieving the ‘personal best” may lead to a relapse of symptoms
as their absence does not rule out the presence of airways obstruction and active
disease. Hence, the GINA 2014 guidelines also emphasize that lung function should
have reached a plateau before considering stepping-down.[1]
There is a caveat on the application of spirometry. The information obtained on spirometry
may be misleading if meticulous quality control is not exercised in equipment selection
and maintenance, calibration, operator training and competence, and patient performance.[12]
It is also imperative that prediction equations developed in local population be used
for interpretation of data and avoid misclassification that are inevitable if inappropriate
equations are used. The equations for Indian population, using current standardization
of spirometry, have been published recently.[15]